Your browser does not support java script. Skip navigation
Loading, please wait  Loading, please wait...

33rd Psychiatric Pharmacotherapy Update 2021 - Live and Virtual


2021 Virtual Event - Now Fully On-Demand

 
 

The University of Texas College of Pharmacy welcomes you to the 33rd Psychiatric Pharmacotherapy Update.  This CE activity offers 20 hours of psychiatric focused continuing education.


VIRTUAL LIVE BROADCAST

This program is now fully on-demand.  Must of the content was broadcased live on October 21 and 22.  You many now experience the Psychiatric Pharmacotherapy Update from the comfort of your office or home.  Recordings of all live programming are now available On-Demand for you to view and complete CE over the next year!

Additional On-Demand Content

The Psychiatric Pharmacotherapy Update also offers additional On-Demand content that is available to all registrants.  On-Demand content includes an additional 8 video-based CE programs that may be viewed at anytime over the next year.  This allows registrants to pick and choose the options that fit best with their personal practice.

 

Registration / Access Content Information:

  1. Scroll down and click on the "register now" button.  Set up a new ID or log in to your existing account.  Use the "forgot password" feature to retrieve your log on information.
  2. Bookmark this page!  This is the same log on site that will be used during the event for viewing presentation slides, viewing the live broadcasts, access on-demand sessions and access to complete evaluations for CE credit.
  3. Anytime, return to this page, log in, (if it does not return you automatically to this page, just click the "Assess Content" in the banner on the home page). Then scroll down below, and you will see the webinar links and content inside the tabs below.
For more information, please see the conference full website here.
 

Continuing Education Information: https://sites.utexas.edu/cpe-ppu/agenda/ce-credits/
 
CPE:  The University of Texas at Austin College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  This two-day activity is approved for 2.0 CEUs (20 contact hours) of continuing education credit.  In order to receive 20.5 contact hours of CE credit, the participant must attend/participate in all sessions of the program, and complete the online evaluations for each session.

CME: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The UT Health San Antonio Joe R. & Teresa Lozano Long School of Medicine and The University of Texas at Austin College of Pharmacy. The Joe R. & Teresa Lozano Long San Antonio School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Long School of Medicine designates this live activity for a maximum of 20 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Social Work / Counseling / APA: The Office of Professional Development at The University of Texas at Austin Steve Hicks School of Social Work is accredited by the Council on Social Work Education, and as such receives automatic approval as a continuing education provider by the Texas Board of Social Work Examiners under Texas Administrative Code, Title 22, Part 34. § 781.511(c). The program represented by this certificate was provided in accordance with the criteria and standards of the Texas State Board of Social Worker Examiners, and has been approved for Social Workers, Licensed Professional Counselors, and Licensed Marriage and Family Therapists.  Please note that 1 hour = 1 CEU.  Complaints about this program may be made to TSBSWE  333 Guadalupe St, Tower 3, Room 900, Austin, TX 78701  •  512-305-7700 • 800-821-3205

bhec.texas.gov/texas-state-board-of-social-worker-examiners/


CNE:  This activity has been submitted to University of Texas at Austin School of Nursing for approval to award contact hours. University of Texas at Austin School of Nursing is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

 

Date: Oct 21, 2021 08:30 AM - Oct 22, 2021 04:30 PM

Fee

$425.00

CE Hours

20.50

CE Units

2.050

Registration closes on Oct 22, 2021 01:00 AM

Activity Type

  • Knowledge

 

 

Registration closes on Oct 22, 2021 at 01:00 AM

Registration Closed  

 
Psychotropic New Drug Update
 
 
Stephen R. Saklad, Phrm.D., BCPP
Clinical Professor of Pharmacotherapy
Director, Psychiatric Pharmacy Program
Adjoint Professor, School of Medicine
Clinical Pharmacologist, San Antonio State Hospital, Texas Department of State Health Services
 
 
 
LEARNING OBJECTIVES
  • Describe the pharmacology, adverse effects, drug interactions, therapeutic uses, and dosing of selected psychiatric drugs recently marketed as well as drugs approaching the market.
  • Review pharmacology, adverse effects, drug interactions, therapeutic uses, and dosing of selected psychiatric drugs that have been released in the past five years.
ABOUT THE FACULTY

Dr. Saklad was born in Los Angeles, California in 1953, and graduated from Pacific Palisades High School in 1970. He received his baccalaureate degree cum laude in Bacteriology from the University of California, Los Angeles in 1974. His Doctor of Pharmacy degree was earned at the University of Southern California in 1978. He had a National Institute of Mental Health training fellowship in Psychiatric Pharmacy supervised by Jim Wilson, Pharm.D., BCPP at the Nebraska Psychiatric Institute of the University of Nebraska Medical Center at Omaha in 1978-9. He then joined the faculty of The University of Texas at Austin College of Pharmacy and the clinical staff at San Antonio State Hospital (SASH) in 1979. He was the first clinical pharmacist employed by the Texas Department of Mental Health and Mental Retardation (now Texas Health and Human Services) when he began as Clinical Coordinator at SASH. He has lived in San Antonio, Texas since 1979. He is married and the father of triplet sons.

During his 38 years career, Dr. Saklad has provided clinical care, education, and research in a variety of settings and treatment roles at SASH. He team teaches didactic courses for second and third professional year pharmacy students. He is the course director for Advanced Pharmacotherapy Laboratory, a third professional year opportunity for students to develop their clinical presentation skills that is given across four campuses. He precepts and mentors third and fourth professional year pharmacy students (P3’s & P4’s) at SASH. He received the UT Austin College of Pharmacy’s Teaching Award from the Class of 2014. He authored and successfully discussed with members of the Texas Legislature the creation of a clinical research unit at SASH that was funded by the Texas Legislature and jointly governed by the UT Austin College of Pharmacy, UT Health Science Center San Antonio Department of Psychiatry and SASH.

Dr. Saklad initiated and developed the first websites for the UT Austin College of Pharmacy in 1994, the College of Psychiatric and Neurologic Pharmacists (CPNP) in 1997, and the CPNP Foundation in 2015. He helped to design, organize and was a founding member of CPNP when it incorporated in 1998 as well as the CPNP Foundation in 2012. In 2003, he was elected to the Board of Directors of the CPNP for a two-year term. He has served as a member or officer of the CPNP Communications Committee since the creation of CPNP from 1995 to 2011 and was the Founding Senior Editor of the Mental Health Clinician, CPNP’s Open Access journal, from 2011-13. Currently, Dr. Saklad is Treasurer of the CPNP Foundation a member of the CPNP Business Development Committee. He was on the task force that developed The Mental Health Pharmacy Directory to improve patient access. He is the Director of The University of Texas Psychiatric Pharmacy Program. In 1988, he helped to create and has chaired The University of Texas at Austin College of Pharmacy’s Psychiatric Pharmacotherapy Update since 2007.

Dr. Saklad publishes articles and presents to many groups around the country on a variety of pharmacy and mental health-related topics. He edited Psychopharmacology Update newsletter from 1998-2002 and edited two editions of a compendium based upon this newsletter, Psychopharmacology Desktop Reference, published by Manisses Communications Group in 1999 and 2002. He provides updates on his Twitter feed on a variety of topics @pharmacopsych.

Dr. Saklad is a principal or co-investigator for several studies of the efficacy and adverse effects of Phase II, III, and IV psychotropic agents in schizophrenia, mood disorders, depression, and other serious and persistent mental illness, as well as their pharmacokinetics and interactions. He was the Director of UT Health Science Center San Antonio’s Advanced Pharmacotherapy Research with research facilities located at Laurel Ridge Treatment Center and President of Alamo Superior Research, LLC. He has been affiliated with the Behavioral Wellness (“Be Well”) Center, Department of Psychiatry, UT Health San Antonio since 2009.


Disclosure: Dr. Saklad has the following relevant financial relationships, potential or perceived, with commercial or conflicts of interest to disclose:

Employee of Texas Department of Health Services San Antonio
Speakers Bureau: Actavis, Otsuka, Sunovion
Consultant: Janssen, Jazz, Otsuka, Teva
Other: Member of Pharmacists Foundation, Business Development Council for San Antonio
 
Review of Conflicts Policy: The UT Austin College of Pharmacy has a very strict policy to ensure against commercial conflicts of interest in CE programming. For this conference, the planning committee picks two committee members who have appropriate backgrounds to review content, and report any potential conflict of interest to the CPE Director. If conflict issues are discovered, they are addressed with speakers to make appropriate changes. Evaluations are collected from all participants with specific questions around the listed conflicts of commercial interest.
 
 

Activity Number

0067-0000-21-187-H01-P

Release Date: Oct 21, 2021
Credit Expiration Date: Oct 20, 2024

CE Hours

1.00
Registration Closed  

Registration Closed  

 
Reducing Suicide Among Youth, Their Families and Communities with the Columbia Protocol
 
 
Kelly Posner Gerstenhaber, PhD
Professor, Columbia University
Founder and Director, The Columbia Lighthouse Project
Recipient, Secretary of Defense Medal for Exceptional Public Service
Columbia University/New York State Psychiatric Institute
 
 
 
LEARNING OBJECTIVES
  • Discuss how preventative suicide screening models can be used to identify at-risk individuals and establish care plans that reduce suicide while allocating resources effectively.
  • Utilize a systemic best-practice measurement, the C-SSRS, to identify suicidal ideation and behavior to improve risk identification and safety monitoring, which ultimately aids prevention.
  • Demonstrate how the C-SSRS enables more streamlined triage, provides liability protection and facilitates care delivery to those at highest risk.
  • Identify steps taken to implement a comprehensive screening program within an agency.
ABOUT THE FACULTY
 
Dr. Kelly Posner’s work is saving lives all over the globe across 6 continents. The President of the American Psychiatric Association noted her work with the Columbia Protocol could be “like the introduction of antibiotics.” The U.S. Department of Defense said that her work is “nothing short of a miracle,” and that “her effective model of improving the world will help propel us closer to a world without suicide.” Dr. Posner’s work has been noted in a keynote speech at the White House and cited in Congressional hearings, and she gave the lead presentation in a U.S. Senate forum on school safety after the Parkland tragedy. Through her advocacy, she has changed local, national and international policy, which in turn has helped achieve reductions in suicide across all sectors of society. An Israeli government official said her work “is not only saving millions of lives but in Israel it is literally changing the way we live our lives.” The Columbia Protocol is policy across all 50 states, national agencies, and most countries. Dr. Posner’s scholarly work has been included in the compendium of the most important research in the history of the study of suicide, and in 2018 she was awarded The Secretary of Defense Medal for Exceptional Public Service.

Disclosure: Dr. Posner has the following relevant financial relationships, potential or perceived, with commercial or conflicts of interest to disclose: 
Receives royalties from the use of the C-SSRS in pharmaceutical trials
 
Review of Conflicts Policy: The UT Austin College of Pharmacy has a very strict policy to ensure against commercial conflicts of interest in CE programming. For this conference, the planning committee picks two committee members who have appropriate backgrounds to review content, and report any potential conflict of interest to the CPE Director. If conflict issues are discovered, they are addressed with speakers to make appropriate changes. Evaluations are collected from all participants with specific questions around the listed conflicts of commercial interest.
 
 

Activity Number

0067-0000-21-188-H04-P

Release Date: Oct 21, 2021
Credit Expiration Date: Oct 20, 2024

CE Hours

1.00
Registration Closed  

Registration Closed  

 
Update on Childhood Aggression
 
 
Joseph Blader, PhD
Meadows Foundation & Semp Russ Professor of Child Psychiatry 
Departments of Psychiatry & Behavioral Sciences and Pediatrics 
Joe R. and Teresa Lozano Long School of Medicine
University of Texas Health Science Center at San Antonio
 
 
LEARNING OBJECTIVES
  • Discuss current non-pharmacological and pharmacological strategies for treatment of aggression among children with psychiatric disorders
  • Discuss growing evidence to support the treatment of aggression associated with externalizing disorders in children and adolescents.
  • Adverse effect liabilities of pharmacotherapies often used for aggressive behavior • Discuss step approach to treatments, and societal concerns about medications for behavioral disorders in youth.
ABOUT THE FACULTY

Dr. Blader is a child and adolescent clinical psychologist who received his undergraduate education at Tufts University and obtained his doctoral degree in psychology at Queen’s University in Ontario, Canada. He completed clinical training at the Children’s Hospital of Eastern Ontario in Ottawa. He has held clinical and faculty positions North Shore – Long Island Jewish Medical Center, New York University School of Medicine, Albert Einstein College of Medicine and the State University of New York at Stony Brook.


Disclosure: Dr. Blader has the following relevant financial relationships, potential or perceived, with commercial or conflicts of interest to disclose:

Consultant: Supernus Pharmaceuticals
 
Review of Conflicts Policy: The UT Austin College of Pharmacy has a very strict policy to ensure against commercial conflicts of interest in CE programming. For this conference, the planning committee picks two committee members who have appropriate backgrounds to review content, and report any potential conflict of interest to the CPE Director. If conflict issues are discovered, they are addressed with speakers to make appropriate changes. Evaluations are collected from all participants with specific questions around the listed conflicts of commercial interest.
 
 

Activity Number

0067-0000-21-189-H04-P

Release Date: Oct 21, 2021
Credit Expiration Date: Oct 20, 2024

CE Hours

1.00
Registration Closed  

Registration Closed  

 
Treatment of Psychiatric Symptoms in Neurocognitive Disorders
 
 
Jason Schillerstrom, M.D.
Professor, Department of Psychiatry
The University of Texas Health Science Center San Antonio  
 
 
LEARNING OBJECTIVES
  • Review new and emerging therapies as well as risks associated with current pharmacotherapies
  • Evaluate evidence and risk vs. benefit of medication treatment as well as any nonmedication modalities
  • Review current blackbox warnings and potential ethical issues related to patient communication
ABOUT THE FACULTY

Dr. Jason Schillerstrom is a Professor of Geriatric Psychiatry at UT Health San Antonio. He provides clinical care to elders with mood, anxiety, and cognitive disorders. He serves as a consultant to Adult Protective Services and local attorneys who request decisional capacity assessments for elders suffering from neglect or exploitation. Dr. Schillerstrom is the Residency Program Director for Psychiatry where he teaches and guides 78 civilian and active duty psychiatrists in training.

Disclosure: Dr. Schillerstrom has no relevant financial relationship(s), potential or perceived, with commercial or conflicts of interest to disclose.

 
 

Activity Number

0067-0000-21-190-H04-P

Release Date: Oct 21, 2021
Credit Expiration Date: Oct 20, 2024

CE Hours

1.00
Registration Closed  

Registration Closed  

 
Appropriate Use of Complementary and Alternative Medicines (CAM) for Psychiatric Disorders
 
 
Marisa S. P. Toups, M.D.
Psychiatrist
Singularity Psychiatry and Mental Health
 
 
LEARNING OBJECTIVES
  • Discuss often used complementary and alternative medicines (CAM) often used in psychiatric treatments
  • Review evidence to evaluate agents that may be beneficial vs no benefit
  • Discuss potential ethical issues related to use of CAM in psychiatric treatments
ABOUT THE FACULTY

Dr. Toups is a clinician scientist specializing in the study of the interplay between physical and mental functions in health and disease. Her work focuses on understanding the effects of medical illness, particularly chronic inflammatory disorders, on mood and function. She completed a clinical research fellowship at the Center for Depression Research and Clinical Care at UT Southwestern in Dallas, TX and is an expert in the management of treatment resistant depression with a special interest in patients with co-morbid autoimmune and metabolic disorders. She also has extensive experience in clinical trials developing new ways of assessing and treating depression.

Dr. Toups’ current research focuses on understanding specific mechanisms of bi-directional communication between the brain and immune system. Imbalance in this communication increases the risk of depression, as well as chronic inflammatory disorders such as diabetes. Dr. Toups is using genomic, gene expression, and metabolic analyses to better understand why some people are more vulnerable to this maladaptive pattern of brain-immune function with the ultimate goal of identifying targets for future therapies.

Disclosure: Dr Toups has no relevant financial relationship(s), potential or perceived, with commercial or conflicts of interest to disclose.

 
 

Activity Number

0067-0000-21-191-H04-P

Release Date: Oct 21, 2021
Credit Expiration Date: Oct 20, 2024

CE Hours

1.00
Registration Closed  

Registration Closed  

 
Managing Dual Diagnosis: Substance Use and Psychiatric Disorders
 
 
Amanda Simonton, PhD, APRN, PMHNP-BC
Clinical Assistant Professor
The University of Texas at Austin School of Nursing
 
 
LEARNING OBJECTIVES
  • Discuss the context of dual-diagnosis and diagnostic considerations
  • Recall medication considerations and treatment caveats associated with dual-diagnosed disorders
  • Implement trauma-informed care principles into practice
ABOUT THE FACULTY

Amanda J. Simonton, PhD, APRN, PMHNP-BC is a Clinical Assistant Professor at the University of Texas at Austin School of Nursing and Psychiatric Mental Health Nurse Practitioner at the Texas Child Study Center at Dell Children’s Medical Center. She has been a Registered Nurse since 2013 and previously worked in the Intermediate Care Unit at Seton Medical Center Austin and Psychiatric Emergency Department at University Medical Center Brackenridge. As a psychiatric nurse practitioner, she has primarily worked with adults with dual-diagnosed (substance use and mental health) disorders and with children and adolescents. She earned her Bachelor of Science in Nursing (’13), Master of Science in Nursing (’18), and Doctor of Philosophy (’20) through the School of Nursing at the University of Texas at Austin. She is active in presenting at the annual conferences for Texas Nurse Practitioners and the American Psychiatric Nurses Association. She is currently on the Policy Council for Texas Nurse Practitioners and the President-Elect on the American Psychiatric Nurses Association Texas Chapter Board of Directors. Dr. Simonton is also a member of two steering committees, which focus on treatment of schizophrenia spectrum disorders and bipolar depression, for Medscape Inc. Her research and clinical interests are to improve the lives of individuals with substance use disorders and serious mental illness by utilizing evidence-based care and best-practices in the field of psychiatry and psychology.

Disclosure: Dr. Simonton has no relevant financial relationship(s), potential or perceived, with commercial or conflicts of interest to disclose.

 
 

Activity Number

0067-0000-21-192-L04-P

Release Date: Oct 21, 2021
Credit Expiration Date: Oct 20, 2024

CE Hours

1.00
Registration Closed  

Registration Closed  

 
Schizophrenia Update
 
 
Troy A. Moore, Pharm.D., M.S, BCPP
Director ASHP Accredited PGY-1 Pharmacy Residency Program
Clinical Pharmacy Specialist, Mental Health
Rocky Mountain Regional VA Medical Center
 
 
LEARNING OBJECTIVES
  • Assess the impact of co-occurring disorders on schizophrenia
  • Discriminate between the new potential drug targets in schizophrenia and how they may impact the treatment of schizophrenia
  • Evaluate some of the new literature examining medication treatment in schizophrenia and how it will impact outcomes
ABOUT THE FACULTY

Troy A. Moore received his PharmD from the University of New Mexico College of Pharmacy in 2003. He subsequently attended the University of Texas at Austin College, receiving his Master of Science in Pharmacy in 2005 while completing a 2 year Psychiatric Pharmacy at the San Antonio State Hospital and the South Texas Veterans Health Care System (STVHCS). He joined the University of Texas Health Science Center at San Antonio Department of Psychiatry, Division of Schizophrenia and Related Disorders in 2005 and became Assistant Professor in 2007. He joined the STVHCS as Clinical Pharmacy Specialist in Psychiatry in 2010 where he served the Substance Abuse and Domiciliary Programs. He accepted an appointment as the PGY-1 Pharmacy Residency Program Director and Clinical Pharmacy Specialist in Mental Health at the VA Eastern Colorado Health Care System (ECHCS) in Aurora, CO in December 2018. He currently a member of the ECHCS PTSD Clinical Team (PCT) program. He has also been on the planning committee for UT Psych Update since 2007

Disclosure: Dr. Moore has no relevant financial relationship(s), potential or perceived, with commercial or conflicts of interest to disclose.

 
 

Activity Number

0067-0000-21-194-H04-P

Release Date: Oct 21, 2021
Credit Expiration Date: Oct 20, 2024

CE Hours

1.00
Registration Closed  

Registration Closed  

Treating Behavioral Manifestations of Traumatic Brain Injury
 
Muhammad Baig, M.D.
Research Instructor of Psychiatry and Physician
Department of Psychiatry UT Health Science Center San Antonio
 
 
LEARNING OBJECTIVES
  • Describe the classification of Traumatic Brain Injury (TBI).
  • Describe behavioral manifestations of TBI.
  • Discuss the management of individuals with TBI
ABOUT THE FACULTY
 
Muhammad Rais Baig, MD, MS, is a staff physician at the Polytrauma Rehabilitation Center, South Texas Veterans Health Care System (STVHCS), and Assistant Professor in the Department of Psychiatry and Rehabilitation Medicine, University of Texas Health Science Center at San Antonio (UTHSCA). He is board certified in Brain Injury Medicine, Psychosomatic Medicine, and General Adult Psychiatry. He is the site-PI for VA and industry funded multi-center clinical trials. He is a clinical neuropsychiatrist and physician-scientist. His long-term research objectives are to identify, test, and confirm the most effective pharmacological treatment to facilitate recovery of Veterans who suffered combat related trauma.
 
Disclosure: Dr. Baig has no relevant financial relationship(s), potential or perceived, with commercial or conflicts of interest to disclose.
 
 
 

Activity Number

0067-0000-21-195-H04-P

Release Date: Oct 22, 2021
Credit Expiration Date: Oct 21, 2024

CE Hours

1.00
Registration Closed  

Registration Closed  

 
Use of Psychotropic Serum Concentrations in Clinical Practice
 
 
Stephen R. Saklad, Phrm.D., BCPP
Clinical Professor of Pharmacotherapy
Director, Psychiatric Pharmacy Program
Adjoint Professor, School of Medicine
Clinical Pharmacologist, San Antonio State Hospital, Texas Department of State Health Services
 
 
LEARNING OBJECTIVES
  • Review of which medications can have meaningful levels drawn
  • Discuss how to use meaningful levels in clinical practice
  • Discuss subtherapeutic levels / toxic levels
  • Include genetics topic / ethics topic and testing of genetics testing
ABOUT THE FACULTY

Dr. Saklad was born in Los Angeles, California in 1953, and graduated from Pacific Palisades High School in 1970. He received his baccalaureate degree cum laude in Bacteriology from the University of California, Los Angeles in 1974. His Doctor of Pharmacy degree was earned at the University of Southern California in 1978. He had a National Institute of Mental Health training fellowship in Psychiatric Pharmacy supervised by Jim Wilson, Pharm.D., BCPP at the Nebraska Psychiatric Institute of the University of Nebraska Medical Center at Omaha in 1978-9. He then joined the faculty of The University of Texas at Austin College of Pharmacy and the clinical staff at San Antonio State Hospital (SASH) in 1979. He was the first clinical pharmacist employed by the Texas Department of Mental Health and Mental Retardation (now Texas Health and Human Services) when he began as Clinical Coordinator at SASH. He has lived in San Antonio, Texas since 1979. He is married and the father of triplet sons.

During his 38 years career, Dr. Saklad has provided clinical care, education, and research in a variety of settings and treatment roles at SASH. He team teaches didactic courses for second and third professional year pharmacy students. He is the course director for Advanced Pharmacotherapy Laboratory, a third professional year opportunity for students to develop their clinical presentation skills that is given across four campuses. He precepts and mentors third and fourth professional year pharmacy students (P3’s & P4’s) at SASH. He received the UT Austin College of Pharmacy’s Teaching Award from the Class of 2014. He authored and successfully discussed with members of the Texas Legislature the creation of a clinical research unit at SASH that was funded by the Texas Legislature and jointly governed by the UT Austin College of Pharmacy, UT Health Science Center San Antonio Department of Psychiatry and SASH.

Dr. Saklad initiated and developed the first websites for the UT Austin College of Pharmacy in 1994, the College of Psychiatric and Neurologic Pharmacists (CPNP) in 1997, and the CPNP Foundation in 2015. He helped to design, organize and was a founding member of CPNP when it incorporated in 1998 as well as the CPNP Foundation in 2012. In 2003, he was elected to the Board of Directors of the CPNP for a two-year term. He has served as a member or officer of the CPNP Communications Committee since the creation of CPNP from 1995 to 2011 and was the Founding Senior Editor of the Mental Health Clinician, CPNP’s Open Access journal, from 2011-13. Currently, Dr. Saklad is Treasurer of the CPNP Foundation a member of the CPNP Business Development Committee. He was on the task force that developed The Mental Health Pharmacy Directory to improve patient access. He is the Director of The University of Texas Psychiatric Pharmacy Program. In 1988, he helped to create and has chaired The University of Texas at Austin College of Pharmacy’s Psychiatric Pharmacotherapy Update since 2007.

Dr. Saklad publishes articles and presents to many groups around the country on a variety of pharmacy and mental health-related topics. He edited Psychopharmacology Update newsletter from 1998-2002 and edited two editions of a compendium based upon this newsletter, Psychopharmacology Desktop Reference, published by Manisses Communications Group in 1999 and 2002. He provides updates on his Twitter feed on a variety of topics @pharmacopsych.

Dr. Saklad is a principal or co-investigator for several studies of the efficacy and adverse effects of Phase II, III, and IV psychotropic agents in schizophrenia, mood disorders, depression, and other serious and persistent mental illness, as well as their pharmacokinetics and interactions. He was the Director of UT Health Science Center San Antonio’s Advanced Pharmacotherapy Research with research facilities located at Laurel Ridge Treatment Center and President of Alamo Superior Research, LLC. He has been affiliated with the Behavioral Wellness (“Be Well”) Center, Department of Psychiatry, UT Health San Antonio since 2009.


Disclosure: Dr. Saklad has the following relevant financial relationships, potential or perceived, with commercial or conflicts of interest to disclose:

Employee of Texas Department of Health Services San Antonio
Speakers Bureau: Actavis, Otsuka, Sunovion
Consultant: Janssen, Jazz, Otsuka, Teva
Other: Member of Pharmacists Foundation, Business Development Council for San Antonio
 
Review of Conflicts Policy: The UT Austin College of Pharmacy has a very strict policy to ensure against commercial conflicts of interest in CE programming. For this conference, the planning committee picks two committee members who have appropriate backgrounds to review content, and report any potential conflict of interest to the CPE Director. If conflict issues are discovered, they are addressed with speakers to make appropriate changes. Evaluations are collected from all participants with specific questions around the listed conflicts of commercial interest.
 
 
 

Activity Number

0067-0000-21-196-H04-P

Release Date: Oct 22, 2021
Credit Expiration Date: Oct 21, 2024

CE Hours

1.00
Registration Closed  

Registration Closed  

 
Eating Disorder Update
 
 
Sean Kerrigan, M.D.
Psychiatrist
UT Health Austin Pediatric Psychiatry at Dell Children’s
 
Hani Talebi, Ph.D.,
LSSP Director, Pediatric Psychology Texas Child Study Center, Dell Children's Medical Center
Assistant Professor, Dept of Psychiatry and Behavioral Sciences The University of Texas at Austin Dell School of Medicine
 
 
LEARNING OBJECTIVES
  • Discuss evidence-based treatments for eating disorders
  • Discuss Vyvanse use for binge eating disorder
  • Discuss role of psychotherapy and other approaches in the treatment of eating disorders
ABOUT THE FACULTY
 
Hani Talebi, PhD, LSSP, is a licensed pediatric psychologist and the Director of Pediatric Psychology for UT Health Austin Pediatric Psychiatry at Dell Children’s. With more than 20 years of experience, he specializes in consultation/liaison psychology, parent management training, and brief evidence-based interventions for medically fragile children. Additionally, Dr. Talebi is an assistant professor in the Dell Medical School Department of Psychiatry and Behavioral Sciences. Dr. Talebi earned his combined doctorate in clinical, counseling, and school psychology with a specialization in clinical child and adolescent psychology from the University of California, Santa Barbara and his bachelor’s in cognitive science with a focus on infant cognition and evidence-based treatment of externalizing behavior disorders from the University of California, Irvine. He completed an internship in pediatric psychology at the Children’s Hospital of Orange County and a fellowship pediatric trauma at Child Abuse Listening and Mediation at the University of California, Santa Barbara. He also completed a clinical research assistantship at Children’s National Medical Center, where he oversaw clinical trials investigating the efficacy of various interventions for attention-deficit/hyperactivity disorder and other comorbid conditions. Dr. Talebi currently serves as the psychology service chief for the Consultation/Liaison Mental Health team at Dell Children’s Medical Center. He has accrued technical aptitude in numerous evidence-based modalities, including individual and group cognitive behavioral therapy, behavioral classroom management and parent training, and motivational interviewing. His research interests focus on decreasing all hospital readmission rates for children diagnosed with chronic illness.
 
Disclosure: Dr. Talebi has no relevant financial relationship(s), potential or perceived, with commercial or conflicts of interest to disclose.
 

Sean Kerrigan, M.D., is an assistant professor in the Department of Psychiatry at Dell Medical School and a child and adolescent psychiatrist at Dell Children’s Medical Center. Kerrigan has clinical interests in eating disorders, family-based treatment, anxiety disorders, pediatric psychopharmacology and inpatient mental health treatment. Kerrigan received his medical degree at the Louisiana State University School of Medicine in New Orleans and was awarded both the Board of Supervisors Scholarship and the Phi Kappa Phi Fellowship for academic achievement. After discovering a passion for mental health, he completed his psychiatry residency at Harvard Medical School, training at Brigham and Women’s Hospital, Beth Israel Deaconess and Children’s Hospital Boston. He then completed a two-year fellowship in child and adolescent psychiatry at Stanford University, where he practiced in clinics focused on anxiety and eating disorders research. Prior to joining the faculty at Dell Medical School, he served as the medical director for an adolescent residential treatment center and an attending psychiatrist for The Outlook, an inpatient eating disorders program at Weill Cornell and New York-Presbyterian Hospital.

In addition to his clinical and administrative roles, Kerrigan enjoys the opportunity to teach medical students and supervise psychiatry residents in training through Dell Medical School. He is a published author, has led multiple community-focused educational initiatives around the early recognition and prevention of eating disorders and is a frequent contributor to both local and international medical conferences.

Disclosure: Dr. Kerrigan has no relevant financial relationship(s), potential or perceived, with commercial or conflicts of interest to disclose.

 
 

Activity Number

0067-0000-21-197-H04-P

Release Date: Oct 22, 2021
Credit Expiration Date: Oct 21, 2024

CE Hours

1.00
Registration Closed  

Registration Closed  

 
Evaluating the Evidence for Teratogenicity of Psychotropic Medications
 
 
Jeffrey Newport, M.D.
Director of Women’s Reproductive Mental Health
UT Health Austin
 
 
LEARNING OBJECTIVES
  • Review evidence-based data regarding potential teratogenicity of psychotropic medications
  • Discuss best practices regarding use of psychotropic medications during and after pregnancy
ABOUT THE FACULTY
Jeffrey Newport is Professor of Psychiatry and Women’s Health at the University of Texas at Austin Dell Medical School where he serves as Associate Chair for Research for the Department of Psychiatry & Behavioral Sciences and Director of Texas Women’s Reproductive Mental Health.. Dr. Newport completed a graduate theological degree before receiving his medical degree from the University of South Carolina. He subsequently completed psychiatric residency and a master’s degree in clinical research at Emory University. His awards include the NARSAD Independent and Young Investigator Awards, Young Faculty Award from the American Psychiatric Institute for Research and Education, the Society of Biological Psychiatry’s Lilly Fellowship, the American College of Psychiatrists’ Laughlin Fellowship, and the Distinguished Physician Alumnus Award from the University of South Carolina. He has published in leading journals across numerous specialties including JAMA, American Journal of Psychiatry, American Journal of Obstetrics & Gynecology, Neurology, and Pediatrics. Dr. Newport’s research focuses on women’s mental health with an emphasis on the psychobiology of perinatal psychiatric disorders, psychotropic pharmacokinetics during pregnancy and lactation, and the persistent biobehavioral impact of childhood trauma and other early life adverse experiences.

Disclosure: Dr. Newport has the following relevant financial relationships, potential or perceived, with commercial or conflicts of interest to disclose:

Grant/Research Support: Eli Lilly, Glaxo Smith Kline, Janssen, Sage Therapeutics, Takeda Pharmaceuticals, Wyeth
Honorarium: Astra-Zeneca, Glaxo Smith Kline, Janssen, Sage Therapeutics, Takeda Pharmaceuticals, Wyeth

Review of Conflicts Policy: The UT Austin College of Pharmacy has a very strict policy to ensure against commercial conflicts of interest in CE programming. For this conference, the planning committee picks two committee members who have appropriate backgrounds to review content, and report any potential conflict of interest to the CPE Director. If conflict issues are discovered, they are addressed with speakers to make appropriate changes. Evaluations are collected from all participants with specific questions around the listed conflicts of commercial interest.

 
 

Activity Number

0067-0000-21-198-H04-P

Release Date: Oct 22, 2021
Credit Expiration Date: Oct 21, 2024

CE Hours

1.00
Registration Closed  

Registration Closed  

 
The Management of Behavioral and Psychological Symptoms of Dementia (BPSD) in the Era of Boxed Warnings
 
 
Rajesh R. Tampi, M.D., M.S., D.F.A.P.A
Professor of Psychiatry
Case Western Reserve University School of Medicine
Associate Clinical Professor of Psychiatry, Yale School of Medicine
President Elect, American Association for Geriatric Psychiatry
 
 
LEARNING OBJECTIVES
  • Describe the efficacy and safety data of the emerging and recently approved psychiatric and neurologic medication pipeline.
  • Discuss appropriate monitoring requirements, patient education points, and provider education for these agents.
  • Discuss clinical use of new and emerging medications
ABOUT THE FACULTY

Dr. Tampi is the Chairman, Department of Psychiatry & Behavioral Sciences, Cleveland Clinic Akron General, Akron, Ohio and the Chief, Section for Geriatric Psychiatry, Cleveland Clinic in Cleveland, Ohio. In addition, he is a Professor of Medicine, Cleveland Clinic Learner College of Medicine of Case Western Reserve University and a Professor of Psychiatry at North East Ohio Medical University. Dr. Tampi also maintains his appointment as an Adjunct Professor of Psychiatry at Yale School of Medicine, New Haven, Connecticut.  Dr. Tampi is the Past President of the American Association for Geriatric Psychiatry (AAGP). He was the President of the AAGP for 2019-2020 and the Co-President for 2020-2021. Dr. Tampi was the Secretary and Treasurer of the AAGP for 2017-2018. He was the Program Chair for the 2017 AAGP Annual Meeting, Dallas, Texas. Dr. Tampi is the Past President of the International Medical Graduates (IMG) Caucus at the American Psychiatric Association (APA). He is a Distinguished Fellow of the APA and of the AAGP.

Dr. Tampi is a graduate of the University of Kerala, Kerala, India. He trained in Psychiatry at the University of Leeds, Leeds, England and at the University of Vermont, Burlington, Vermont. During his residency training in England, Dr. Tampi also attained a Post Graduate Diploma in Clinical Psychiatry from the University of Leeds. He completed his Geriatric Psychiatry Fellowship at Yale School of Medicine.  Dr. Tampi has received three ‘Outstanding Teaching Attending Awards’ and the ‘Chairman’s Award’ for outstanding teaching, research and clinical work from the Department of Psychiatry at Yale School of Medicine. He received the ‘Teacher of the Year’ Award from the Department of Psychiatry, Case Western Reserve University MetroHealth Program in 2015, 2016 and 2018.  Dr. Tampi is a recipient of the Geriatric Academic Career Award (GACA) instituted by the Department of Health and Human Services (DHHS). He was a recipient of the AAGP’s ‘Clinician of the Year Award’ in 2013.  Dr. Tampi also received the AAGP’s ‘Recognition and Appreciation’ Certificate in 2018. In 2019, he received the AAGP’s ‘Educator of the Year Award’. Dr. Tampi received the ‘2019 Outstanding Academician of the Year Award’ given by the Indo-American Psychiatric Association (IAPA). He is the recipient of the 2021 Jack Weinberg Award for Geriatric Psychiatry given by the APA.  Dr. Tampi has over 180 publications on various topics in psychiatry and geriatric psychiatry. In addition, he is the Editor of 9 books in psychiatry published by reputed publishers including Lippincott Williams & Wilkins (LWW), Oxford University Press (OUP), Springer International Publishing (SIP) and Cambridge University Press (CUP).

Dr. Tampi serves as the Editor-in-Chief of the World Journal of Psychiatry, Associate Editor for Drugs in Context (Psychiatry), Associate Editor for Aging Psychiatry Section of Frontiers in Psychiatry and the Section Editor of Geriatric Psychiatry for Psychiatric Times. He is on the Editorial Board of ‘Clinical Interventions in Aging’, the ‘Annals of Clinical Psychiatry’ and ‘Therapeutic Advances in Psychopharmacology’. Furthermore, Dr. Tampi serves as an ad-hoc peer reviewer for 52 journals including the American Journal of Geriatric Psychiatry, the American Journal of Psychiatry, JAMA Psychiatry, the Journal of American Geriatrics Society and the American Journal of Alzheimer’s Disease and other Dementias amongst others.  Dr. Tampi’s clinical and research interests are the management of psychiatric disorders in late life, neurodegenerative disorders, ethical & legal issues in geriatric psychiatry, integrated geriatric -psychiatric care and undergraduate and postgraduate education in psychiatry and geriatric psychiatry.

Disclosure: Dr. Tampi has no relevant financial relationship(s), potential or perceived, with commercial or conflicts of interest to disclose. 
 
 

Activity Number

0067-0000-21-200-H04-P

Release Date: Oct 21, 2021
Credit Expiration Date: Oct 20, 2024

CE Hours

1.00
Registration Closed  

Registration Closed  

 
Treatment of Agitation and Impulsivity in Youth with Autism Spectrum Disorder
 
Eric Shute, M.D
Psychiatrist, UT Health Austin Pediatric Psychiatry
Dell Children's Medical Center
 
Mariel Cannady, PsyD
Psychologist, UT Health Austin Pediatric Psychiatry
Dell Children’s Hospital
 
 
LEARNING OBJECTIVES
  • Describe agitation and impulsivity as features of emotion dysregulation common in ASD
  • Introduce evidence-based behavioral strategies for management of emotion dysregulation in youth with ASD
  • Introduce evidence-based pharmacological strategies for management of emotion dysregulation, impulsivity and aggression/agitation in autistic youth
  • Describe the evidence base for, and importance of, a multidisciplinary approach to managing the externalized symptoms of neurodiverse youth. 
ABOUT THE FACULTY

Mariel Cannady, Psy.D., is an assistant professor in the Department of Psychiatry and Behavioral Sciences and a licensed child and adolescent psychologist in UT Health Austin Pediatric Psychiatry at Dell Children’s. She specializes in treating children with anxiety, neurodevelopmental disorders and challenging behaviors.  Cannady earned both her Doctor of Psychology degree in clinical and school psychology and her educational specialist degree in school psychology from James Madison University. She completed her internship in child clinical/pediatric psychology at the Texas Child Study Center.  Cannady has interdisciplinary training in neurodevelopmental disorders through the LEND program at Virginia Commonwealth University’s Center for Excellence in Developmental Disabilities. She is a graduate of the International OCD Foundation’s Intensive Pediatric Behavior Therapy Training Institute and has specialized training in behavior therapy, applied behavior analysis, cognitive-behavioral therapy and parent-child interaction therapy.  Cannady’s research interests include family engagement in pediatric treatment and parent-child interactions among children with neurodevelopmental disabilities. Her published research includes identifying determinants for successful transition to adult care among young people with special health care needs.

Disclosure: Dr. Cannady has no relevant financial relationship(s), potential or perceived, with commercial or conflicts of interest to disclose.


Hani Talebi, Ph.D., LSSP, is an affiliate faculty member in the Department of Psychiatry and Behavioral Sciences and a courtesy affiliate faculty member in the UT Austin’s Departments of Pediatrics and Educational Psychology. Formerly the director of pediatric psychology, Talebi is also a licensed pediatric psychologist and licensed specialist in school psychology.

Talebi earned his combined doctorate in clinical, counseling and school psychology with a specialization in clinical child and adolescent psychology from the University of California, Santa Barbara, and his bachelor’s in cognitive science with a focus on infant cognition and evidence-based treatment of externalizing behavior disorders from the University of California, Irvine. He completed an internship in pediatric psychology at the Children’s Hospital of Orange County and a fellowship in pediatric trauma at Child Abuse Listening and Mediation at the University of California, Santa Barbara. He also completed a clinical research assistantship at Children’s National Medical Center, where he oversaw clinical trials investigating the efficacy of various interventions for attention-deficit hyperactivity disorder and other co-morbid conditions.

Talebi currently serves as the vice president of health system integration at the Meadows Mental Health Policy Institute. In addition to technical aptitude in numerous evidence-based modalities, his administrative efforts at the juncture of the medical and mental health models have resulted in innovative program development, various quality improvement initiatives and fiscally sustainable service provision platforms across milieus. His research interests focus on pediatric trauma, contextually relevant supervision practices on the C/L milieu and decreasing all hospital readmission rates for children diagnosed with chronic illness.

Disclosure: Dr. Talebi has no relevant financial relationship(s), potential or perceived, with commercial or conflicts of interest to disclose.

 
 

Activity Number

0067-0000-21-201-H04-P

Release Date: Oct 22, 2021
Credit Expiration Date: Oct 20, 2024

CE Hours

1.00
Registration Closed  

Registration Closed  

 
Acute Pain Management with Patients with OUD
 
 
Kirsten Mason, PharmD, BCPS
Regional Clinical Pharmacy Manager
Ascension Texas
 
 
LEARNING OBJECTIVES
  • Develop an approach to manage pain with hospitalized individuals with opioid use disorder (OUD)
  • Compare pain management strategies for individuals with OUD taking buprenorphine, methadone, extended release naltrexone, and non-prescribed opioids
  • Review transitions of care considerations for patients with OUD
ABOUT THE FACULTY

Dr. Kirsten Mason is a graduate of the University of Tennessee Health Science Center College of Pharmacy. She completed her PGY1 Pharmacy Residency at Memphis Veterans Affairs Medical Center and her PGY2 Internal Medicine Residency at University Medical Center Brackenridge in Austin, TX. Immediately after residency training, Dr. Mason accepted a clinical pharmacy specialist position in cardiology at Northwestern Memorial Hospital in Chicago. In 2016, she had an opportunity to relocate back to Austin and she joined Dell Seton Medical Center at University of Texas as an Internal Medicine Clinical Pharmacy Specialist. In this role, she assisted in the development of an inpatient opioid use disorder treatment service. In November of 2018, Dr. Mason transitioned roles within Ascension Texas to a Regional Clinical Pharmacy Manager with an emphasis on project management and pain management. She also serves as a preceptor for University of Texas College of Pharmacy and Texas A&M College of Pharmacy. Dr. Mason continues to advocate for treatment of opioid use disorder across the continuum of care and educate healthcare providers about medications for opioid use disorder. More recently, Dr. Mason is serving as Interim Director of Pharmacy at Ascension Seton Northwest.


Disclosure: Dr. Mason has the following relevant financial relationships, potential or perceived, with commercial or conflicts of interest to disclose:

Consultant: Macromoltek Grant Consultant

Review of Conflicts Policy: The UT Austin College of Pharmacy has a very strict policy to ensure against commercial conflicts of interest in CE programming. For this conference, the planning committee picks two committee members who have appropriate backgrounds to review content, and report any potential conflict of interest to the CPE Director. If conflict issues are discovered, they are addressed with speakers to make appropriate changes. Evaluations are collected from all participants with specific questions around the listed conflicts of commercial interest.

 This project is funded by Texas Health & Human Services Texas Targeted Opioid Response.

Activity Number

0067-0000-21-108-H08-P/T

Release Date: Oct 21, 2021
Credit Expiration Date: Oct 20, 2024

CE Hours

1.00
Registration Closed  

Registration Closed  

 
Role of Stigma in Opioid Use Disorder
 
 
Richard Bottner, PA-C
Assistant Professor, Department of Internal Medicine
The University of Texas at Austin Dell Medical School
 
 
LEARNING OBJECTIVES
  • Define stigma and its historical origins
  • Identify different types of stigma
  • Discuss how stigma decreased access to care for people with substance use disorders
 
ABOUT THE FACULTY

Richard Bottner, DHA, PA-C is an Assistant Professor in the Department of Internal Medicine at Dell Medical School at The University of Texas at Austin. Bottner is also a physician assistant in the Division of Hospital medicine at Dell Seton Medical Center. Bottner is the Director of the Buprenorphine Team (B-Team), a full-service consultation team that provides patients who are hospitalized and have opioid use disorder access to treatment and linkage to appropriate outpatient care. The program also works to reduce stigma of patients with substance use disorders. Bottner is also the Director of Support Hospital Opioid Use Treatment (SHOUT) Texas, a TTOR-funded program seeking to increase access to opioid use disorder treatment in hospitals across the state.

Disclosure: Richard Bottner has no relevant financial relationship(s) with commercial interests or conflicts of interest to disclose.

 This project is funded by Texas Health & Human Services Texas Targeted Opioid Response.

Activity Number

0067-0000-21-122-H08-P/T

Release Date: Oct 21, 2021
Credit Expiration Date: Oct 20, 2024

CE Hours

1.00
Registration Closed  

Registration Closed  

 
New Agents for Mental Health and Neurologic Disorders
 
 
Stephen R. Saklad, Phrm.D., BCPP
Clinical Professor of Pharmacotherapy
Director, Psychiatric Pharmacy Program
Adjoint Professor, School of Medicine
Clinical Pharmacologist, San Antonio State Hospital, Texas Department of State Health Services
 
LEARNING OBJECTIVES
  • Describe the efficacy and safety data of the emerging and recently approved psychiatric and neurologic medication pipeline.
  • Discuss appropriate monitoring requirements, patient education points, and provider education for these agents.
  • Discuss clinical use of new and emerging medications
ABOUT THE FACULTY

Dr. Saklad was born in Los Angeles, California in 1953, and graduated from Pacific Palisades High School in 1970. He received his baccalaureate degree cum laude in Bacteriology from the University of California, Los Angeles in 1974. His Doctor of Pharmacy degree was earned at the University of Southern California in 1978. He had a National Institute of Mental Health training fellowship in Psychiatric Pharmacy supervised by Jim Wilson, Pharm.D., BCPP at the Nebraska Psychiatric Institute of the University of Nebraska Medical Center at Omaha in 1978-9. He then joined the faculty of The University of Texas at Austin College of Pharmacy and the clinical staff at San Antonio State Hospital (SASH) in 1979. He was the first clinical pharmacist employed by the Texas Department of Mental Health and Mental Retardation (now Texas Health and Human Services) when he began as Clinical Coordinator at SASH. He has lived in San Antonio, Texas since 1979. He is married and the father of triplet sons.

During his 38 years career, Dr. Saklad has provided clinical care, education, and research in a variety of settings and treatment roles at SASH. He team teaches didactic courses for second and third professional year pharmacy students. He is the course director for Advanced Pharmacotherapy Laboratory, a third professional year opportunity for students to develop their clinical presentation skills that is given across four campuses. He precepts and mentors third and fourth professional year pharmacy students (P3’s & P4’s) at SASH. He received the UT Austin College of Pharmacy’s Teaching Award from the Class of 2014. He authored and successfully discussed with members of the Texas Legislature the creation of a clinical research unit at SASH that was funded by the Texas Legislature and jointly governed by the UT Austin College of Pharmacy, UT Health Science Center San Antonio Department of Psychiatry and SASH.

Dr. Saklad initiated and developed the first websites for the UT Austin College of Pharmacy in 1994, the College of Psychiatric and Neurologic Pharmacists (CPNP) in 1997, and the CPNP Foundation in 2015. He helped to design, organize and was a founding member of CPNP when it incorporated in 1998 as well as the CPNP Foundation in 2012. In 2003, he was elected to the Board of Directors of the CPNP for a two-year term. He has served as a member or officer of the CPNP Communications Committee since the creation of CPNP from 1995 to 2011 and was the Founding Senior Editor of the Mental Health Clinician, CPNP’s Open Access journal, from 2011-13. Currently, Dr. Saklad is Treasurer of the CPNP Foundation a member of the CPNP Business Development Committee. He was on the task force that developed The Mental Health Pharmacy Directory to improve patient access. He is the Director of The University of Texas Psychiatric Pharmacy Program. In 1988, he helped to create and has chaired The University of Texas at Austin College of Pharmacy’s Psychiatric Pharmacotherapy Update since 2007.

Dr. Saklad publishes articles and presents to many groups around the country on a variety of pharmacy and mental health-related topics. He edited Psychopharmacology Update newsletter from 1998-2002 and edited two editions of a compendium based upon this newsletter, Psychopharmacology Desktop Reference, published by Manisses Communications Group in 1999 and 2002. He provides updates on his Twitter feed on a variety of topics @pharmacopsych.

Dr. Saklad is a principal or co-investigator for several studies of the efficacy and adverse effects of Phase II, III, and IV psychotropic agents in schizophrenia, mood disorders, depression, and other serious and persistent mental illness, as well as their pharmacokinetics and interactions. He was the Director of UT Health Science Center San Antonio’s Advanced Pharmacotherapy Research with research facilities located at Laurel Ridge Treatment Center and President of Alamo Superior Research, LLC. He has been affiliated with the Behavioral Wellness (“Be Well”) Center, Department of Psychiatry, UT Health San Antonio since 2009.


Disclosure: Dr. Saklad has the following relevant financial relationships, potential or perceived, with commercial or conflicts of interest to disclose:

Employee of Texas Department of Health Services San Antonio
Speakers Bureau: Actavis, Otsuka, Sunovion
Consultant: Janssen, Jazz, Otsuka, Teva
Other: Member of Pharmacists Foundation, Business Development Council for San Antonio

Review of Conflicts Policy: The UT Austin College of Pharmacy has a very strict policy to ensure against commercial conflicts of interest in CE programming. For this conference, the planning committee picks two committee members who have appropriate backgrounds to review content, and report any potential conflict of interest to the CPE Director. If conflict issues are discovered, they are addressed with speakers to make appropriate changes. Evaluations are collected from all participants with specific questions around the listed conflicts of commercial interest.

 
 

Activity Number

0067-0000-21-199-H04-P

Release Date: Oct 21, 2021
Credit Expiration Date: Jun 20, 2024

CE Hours

1.00
Registration Closed  

Registration Closed  

 
Tardive Dyskinesia Update
 
 
Steve Stoner, PharmD, BCPP
Chair and Clinical Professor
Division of Pharmacy Practice and Administration
University of Missouri - Kansas City School of Pharmacy
 
 
 
LEARNING OBJECTIVES
  • Review 2020 American Psychiatric Association Guidelines for the treatment of patients with schizophrenia who develop tardive dyskinesia.
  • Critique short and long-term treatment considerations for managing tardive dyskinesia and discuss the role of VMAT2 inhibitors in the treatment continuum of tardive dyskinesia
  • Explore the detrimental impact of tardive dyskinesia on global functionality and demonstrate how VMAT2 inhibitors can improve functionality and overall quality of life (e.g., improved mobility, self- care, social activities, and life responsibilities).
ABOUT THE FACULTY
Dr. Steve Stoner is a 1994 graduate of the University of Nebraska College of Pharmacy who also completed a Psychiatric Pharmacy Residency and Fellowship at Western Missouri Mental Health Center (1994-1996). In 1996, Dr. Stoner joined the UMKC School of Pharmacy as a Clinical Assistant Professor and established a clinical practice at the Northwest Missouri Psychiatric Rehabilitation Center where he also started a Psychiatric Pharmacy Residency Program. In 2002, Dr. Stoner was promoted to Clinical Associate Professor and in 2007 was promoted to Clinical Professor. In 2008, he assumed the role of Interim Department Chair of Pharmacy Practice and became the permanent chair in 2008, a position he held until 2020. In 2020, Dr. Stoner was named the Associate Dean for Student Affairs. Dr. Stoner has held several leadership positions within local, regional, and national pharmacy organizations. Notably, Dr. Stoner is a Past-President of the College of Psychiatric and Neurologic Pharmacists Association and within the American Association of Colleges of Pharmacy he has served as the Chair of the Pharmacy Practice Section and Chair of the Council of Sections. Dr. Stoner’s scholarly endeavors have included research efforts in the disease state areas of schizophrenia, depression, drug-induced movements, and bipolar disorder. In addition, he has published in pharmacy education on topics related to course design, student learning outcomes, and student wellness as it relates to the use of smartphone devices. Dr. Stoner has also received several teaching and preceptor awards during his time at UMKC.
 

Disclosure: Dr. Stoner has the following relevant financial relationships, potential or perceived, with commercial or conflicts of interest to disclose:
• Research Grant Support: Alkermes Pharmaceuticals
• Consultant: Neurocrine Pharmaceuticals
• Speaker’s Bureau: Neurocrine Pharmaceuticals
• Honorarium: TEVA Pharmaceuticals
 
Review of Conflicts Policy: The UT Austin College of Pharmacy has a very strict policy to ensure against commercial conflicts of interest in CE programming. For this conference, the planning committee picks two committee members who have appropriate backgrounds to review content, and report any potential conflict of interest to the CPE Director. If conflict issues are discovered, they are addressed with speakers to make appropriate changes. Evaluations are collected from all participants with specific questions around the listed conflicts of commercial interest.
 
 
 

Activity Number

0067-0000-21-203-H04-P

Release Date: Oct 21, 2021
Credit Expiration Date: Oct 20, 2024

CE Hours

1.50
Registration Closed  

Registration Closed  

 
Overcoming Barriers to Clozapine
 
 
Deanna L. Kelly, PharmD., BCPP
Professor of Psychiatry Director, Treatment Research Program (TRP)
Maryland Psychiatric Research Center (MPRC)
University of Maryland School of Medicine
 
 
LEARNING OBJECTIVES
  • Discuss the utility of clozapine in the treatment resistant schizophrenia
  • List significant barriers to the use of clozapine
  • Recognize new data and strategies to overcome some barriers to clozapine use including point of care monitoring, new plasma level assay, and emerging data in patients with Benign Ethnic Neutropenia
ABOUT THE FACULTY
 
Deanna L. Kelly, Pharm.D., BCPP is a Tenured Professor of Psychiatry at the University of Maryland Baltimore School of Medicine and is currently Director of the Treatment Research Program at the Maryland Psychiatric Research Center (MPRC). Dr. Kelly has coauthored and authored 20 books/chapters, published over 220 peer-reviewed articles, presented over 250 scientific posters and has given over 175 invited lectures. In 2017 she was awarded the prestigious Maltz Prize for Innovative and Promising Schizophrenia Research by the Brain and Behavior Research Foundation. https://www.youtube.com/watch?v=y-9lOpPUdg0   She was recently awarded the unsolicited prestigious Method to Extend Research in Time (MERIT) award (R37) from the National Institutes of Mental Health (NIMH) recognizing her research competence and productivity as distinctly superior.    Additionally, her work and scientific expertise has been featured in the New York Times, Women’s Day Magazine, Gluten-Free Living, Vice Media, Clinical Psychiatry News, Psychiatric News and Medscape Medical News.
 
Disclosure: Dr. Kelly has no relevant financial relationship(s) with commercial interests or conflicts of interest to disclose.
 
 
 

Activity Number

0067-0000-21-202-H04-P

Release Date: Oct 21, 2021
Credit Expiration Date: Oct 20, 2024

CE Hours

1.00
Registration Closed  

Registration Closed  

 
Analysis of Drug Diversion
 
 
Diane B. Ginsburg, Ph.D., M.S., R.Ph., FASHP
Clinical Professor, Pharmacy Practice Division
Associate Dean for Healthcare Partnerships
G.D. Searle Endowed Fellow in Pharmacy
The University of Texas at Austin College of Pharmacy
 
 
LEARNING LlanndOBJECTIVES
LEARNING OBJECTIVES
  • Describe drugs involved in diversion and the impact on the opioid crisis
  • Discuss how to identify potential prescribing and diversion red flags and action steps regarding suspicious activities
ABOUT THE FACULTY
Dr. Ginsburg completed her B.S. in Pharmacy at the University of Pittsburgh School of Pharmacy and M.S. at the University of Houston College of Pharmacy.  She completed a two-year ASHP-accredited residency in hospital pharmacy administration at The Methodist Hospital in Houston, Texas.  She received her Doctor of Philosophy degree in higher education administration and leadership in the College of Education at the University of Texas at Austin.  She is currently Clinical Professor in the Pharmacy Practice Division, Associate Dean for Healthcare Partnerships, and G.D. Searle Endowed Fellow in Pharmacy at the University of Texas at Austin, College of Pharmacy.  She is an adjunct instructor in the Drug Enforcement Administration Teaching Academy and a Gallup-Certified Strengths Coach.
 
She has been active with the American Society of Health-System Pharmacists (ASHP) and served as President and a 3-year term on the Board of Directors.  She has served ASHP in several capacities including: Chair, Council on Educational Affairs, AJHP Editorial Advisory Board, Texas Delegate, Co-Coordinator National Clinical Skills Competition.  She is Co-Editor of Infectious Disease Pharmacotherapy Self-Assessment and an author and editor of ASHP’s Preceptor’s Handbook for Pharmacists.  She was inducted as Fellow the ASHP in 1998.  She also served as Chair of the ASHP Research and Education Foundation Board of Directors.
 
She is a Past President of the Texas Society of Health-System Pharmacists (TSHP) and TSHP Research & Education Foundation.  She has received several honors and awards including the 2005 Distinguished Alumnus Award from the University of Pittsburgh School of Pharmacy and is a 2016 recipient of the Texas Ex Students Association Texas Ten Award recognizing the 10 most talented and inspiring professors at the University of Texas at Austin.
Dr. Ginsburg is internationally known for her work on ethics and the legal and regulatory aspects of pharmacy and healthcare.
 
Disclosure: Dr. Ginsburg has no relevant financial relationship(s), potential or perceived, with commercial or conflicts of interest to disclose.
 
 
 

Activity Number

0067-9999-21-152-H01-P

Release Date: Oct 21, 2021
Credit Expiration Date: Oct 20, 2024

CE Hours

1.00
Registration Closed  

Registration Closed  

 
Medication Treatment of Co-Occurring Opioid and Alcohol Use Disorders
 
 
Faculty - Lucas Hill, Pharm.D., BCPS, BCACP
Clinical Associate Professor
The University of Texas at Austin College of Pharmacy
 
 
This session has been switched from a live webinar to an ON-DEMAND session. 
The Video will be placed here once the session is recorded.
We apologize for any inconvenience.
 
 
LEARNING OBJECTIVES
  • Describe recent trends in use and harms of opioids and alcohol
  • Summarize current evidence and key ethical issues related to medication treatment of co-occurring opioid and alcohol use disorders
  • Develop a medication treatment plan for a patient with co-occurring opioid and alcohol use disorders that integrates patient-specific factors relevant to psychiatric clinicians
ABOUT THE FACULTY
 
Lucas G. Hill, PharmD, BCPS, BCACP, graduated from the University of Missouri-Kansas City School of Pharmacy and completed a combined family medicine residency and faculty development fellowship in the University of Pittsburgh Medical Center St. Margaret Department of Family Medicine. He is now a clinical assistant professor at The University of Texas at Austin (UT) College of Pharmacy. Dr. Hill is the director and principal investigator of Operation Naloxone, an interprofessional opioid overdose prevention program funded through the Texas Targeted Opioid Response. His research is focused on clinician-community collaborations to address substance use disorders through evidence-based treatment and harm reduction strategies. Dr. Hill coordinates the first year of the UT Foundations for Interprofessional Collaborative Practice curriculum and serves as lead instructor for a module that trains students from pharmacy, medicine, nursing, and social work to provide team-based care for patients with addiction. He provides an additional 16 hours of addiction-related instruction in the required pharmacy curriculum and precepts both the overdose prevention introductory pharmacy practice experience and the addiction medicine advanced pharmacy practice experience. Dr. Hill currently serves as chair-elect of the American Association of Colleges of Pharmacy Substance Use Disorder Special Interest Group. He is also faculty advisor for the UT Student Pharmacist Recovery Network and co-chair for the UT Opioid Response Consortium. In 2020, Dr. Hill was awarded the American Pharmacists Association Generation Rx Award of Excellence in recognition of his outstanding contributions to addiction-related education.

Disclosure: Dr. Hill receives financial support from the Substance Abuse and Mental Health Services Administration and the Texas Health and Human Services Commission via the Texas Targeted Opioid Response.
 
Review of Conflicts Policy: The UT Austin College of Pharmacy has a very strict policy to ensure against commercial conflicts of interest in CE programming. For this conference, the planning committee picks two committee members who have appropriate backgrounds to review content, and report any potential conflict of interest to the CPE Director. If conflict issues are discovered, they are addressed with speakers to make appropriate changes. Evaluations are collected from all participants with specific questions around the listed conflicts of commercial interest.
 
 
 

Activity Number

0067-0000-21-193-H08-P

Release Date: Oct 21, 2021
Credit Expiration Date: Oct 20, 2024

CE Hours

1.00
Registration Closed  

Registration Closed  

 
Overall Evaluation
 
  • Please complete the overall evaluation providing feedback on the full event.  Your feedback is critical for our future program planning.
  • Thank you for attending and taking time to submit your feedback.
 
 

Registration Closed